References in periodicals archive ?
The LFS was significantly higher in patients who showed a decrease in the breakpoint cluster region and the Abelson leukemia virus ( BCR-ABL ) levels to <10[sup]−3 at day 85 compared with patients who did not reach these levels.[sup][9] A report from the European Working Group on Adult ALL group showed the outcomes of elder patients ( n = 71, all >55 years, median age: 69 years) with dasatinib (140 mg/d, 100 mg/d over 70 years) with low-intensity chemotherapy.